Cytochrome P450-derived renal HETEs: Storage and release  by Carroll, Mairead A. et al.
Kidney International, Vol. 51 (1997), pp. 1696—1702
LABORATORY INVESTIGATION
Cytochrome P450-derived renal HETEs: Storage and release
MAIREAD A. CARROLL, MICHAEL BALAZY, DONG-DONG HUANG, SVETLANA RYBALOVA, J.R. FALCK,
and JOHN C. MCGIFF
Department of Pharmacology, New York Medical College, Valhalla, New York and Department of Molecular Genetics, University of Texas Health Science
Center, Dallas, Texas, USA
Cytochrome P450-derived renal HETEs: Storage and release. We have
established an assay based on gas chromatography-mass spectrometry to
profile and quantitate endogenous cytochrome P450 monooxygenase
(P450)- hydroxyeicosatetraenoic acids (HETEs) exiting the isolated per-
fused rabbit kidney in response to hormonal stimulation. In response to
angiotensin II (Aug II) P450-derived HETEs (16-, 17-, 18-, 19- and 20-)
are released from the isolated Kreb's perfused rabbit kidney. Ang II
produced a several-fold increase in the levels of P450-HETEs above basal
levels in both urinary (such as for 20-HETE from 0.93 0.7 to 2.31 0.9
ng/min) and venous (from 0.1 0.05 to 0.3 0.05 nglmin) effluents.
However, inhibition of P450, which reduced basal release, did not prevent
Aug Il-induced release of P450-AA products from the rabbit kidney; for
example, urinary 20-HETE in the presence of 17-ODYA (1 .rM) was
undetectable and increased to 0.93 0.4 ng/min with Ang II and venous
20-HETE increased from 0.06 0.03 to 0.24 0.07 nglmin. Similar
results were obtained with clotrimazole (1 jiM). As 16-, 18-, 19- and
20-HETEs are vasodilators in the rabbit kidney and 16- and 17-HETEs
inhibit proximal tubular ATPase activity, we investigated their possible
sites of esterification. Cortical and medullary lipids were extracted,
separated by HPLC and P450-HETEs quantitated following alkaline
hydrolysis. The P450-HETEs were incorporated into both neutral lipids
(NL) and phospholipids [phosphatidylethanolamine (PE), phosphatidyl-
inositol (PT), phosphatidylserine (PS) and phosphatidylcholine (PC)1.
However, the assignment of a 1-TETE to a specific phospholipid pool must
be regarded as tentative as the appropriate standards containing P450-
HETEs in the Sn-2 position (such as 20-HETE-PE, 20-HETE-PC, etc.)
were not available. Esterifled HETEs were found in larger quantities in
the cortex as compared to the medulla (34.40 1.12 versus 22.76 0.53
ng/g). The P1 fraction in the cortex yielded the largest quantity of HETEs
and the PC fraction the lowest. In the medulla, the largest quantities of
esterifled HETEs were found in neutral lipids and only slightly lesser
amounts in FE and P1. Esterifled 18-HETE was localized only to the NL
fraction. This fraction also contained the other HETEs, 19- and 20-HETE
being the most abundant. Notably, only 16- and 17-HETE were present in
PE, whereas, 19- and 20-HETE were also present in P1, PS and PC. Thus,
P450-HETEs, like EETs, are stored in the kidney and are, presumably,
subject to release by peptide activation of acylhydrolases.
In response to angiotensin II (Ang IT) cytochrome P450 mono-
oxygenase (P450)-derived hydroxyeicosatetraenoic acids (16-, 17-,
and 18-HETEs), in addition to 19- and 20-HETEs, are released
from the rabbit kidney in amounts equal to or greater than
prostaglandins [1]. The biological activities of the P450-HETEs
are potentially of great importance in view of the preeminent
position of 20-HETE in renal regulatory mechanisms, such as
20-HETE modulates the tubular Na-K-2Cl cotransporter [21
and affects rat preglomerular vascular resistance [3]. We have
established a gas chromatography-mass spectrometry (GC-MS)
assay, based on single ion monitoring, to profile and quantitate
endogenous P450-HETEs exiting the isolated perfused rabbit
kidney in response to hormonal stimulation [1]. Our major
findings are: (1) Vasoactive hormones demonstrate selectivity
with respect to their ability to stimulate renal efflux of HETEs.
Ang II produced a several-fold increase in the levels of P450-
HETEs above basal levels, whereas an equipressor concentration
of AVP did not elevate P450-HETEs in the perfusate above basal
values. Bradykinin (BK), a vasodilator peptide known to stimulate
phospholipase activity, was also without effect on P450-HETEs
efflux from the rabbit kidney. (2) Authentic standards of 16-, 18-,
19- and 20-HETEs dilated the vasculature of the rabbit isolated
kidney, an action dependent on cyclooxygenase activity. (3) The
vasoactivity of 16- and 18-HETEs, unlike 19-HETE isomers, was
stereospecific, in that the (R) configuration was the active isomer.
(4) The effects of P450-HETEs on ion transport were also
stereospecific, the (S) enantiomers of 16- and 17-HETEs being
potent inhibitors of proximal tubular ATPase, whereas their (R)
isomers were virtually inactive.
In this study we have separated venous and urinary perfusates
and quantitated P450-HETE efflux from each compartment. In
addition, we have measured the effects of P450 inhibitors on basal
and Ang II stimulated P450-HETE levels. Although our initial
intent was to profile P450-HETEs produced in response to
vasoactive peptides, which was accomplished, an unexpected and
important finding resulted in reformulating the conceptual basis
for this and subsequent studies. We found that inhibition of P450
monooxygenases did not prevent Ang Il-induced release of P450-
arachidonic acid (AA) products from the rabbit kidney, suggesting
the storage of preformed AA metabolites that are, presumably,
released by peptide activation of acylhydrolases. We, therefore,
investigated possible sites of esterification and describe that
P450-HETEs, like P450-derived cpoxide metabolites of AA in the
rat kidney [4], are preformed in the rabbit kidney and stored in
lipids, from which sites they can be released.
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Preparation of the rabbit isolated, perJised kidney
Male New Zealand White rabbits (2.0 to 2.5 kg) were anesthe-
tized with xylazine (13 mg/kg), ketamine hydrochloride (60 mg/kg)
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and acepromazine (0.7 mg/kg) administered intramuscularly. Fol-
lowing laparotomy, the kidneys were isolated and the renal
arteries cannulated with a blunted angiocath (16 gauge). Krebs'-
Henseleit solution (50 ml) was flushed immediately through each
kidney to remove blood elements. The kidneys were transferred to
a warmed perfusion chamber (37°C) and perfused in a non-
recirculating system under conditions of constant flow at 1
ml/g/min (approximately 10 mI/mm) with Krebs'-Henseleit solu-
tion at 37°C, gassed with 95% 02—5% CO2 [5]. The composition
of the Krebs'-Henseleit solution was (in mM): 118 NaCI, 5.4 KC1,
0.57 MgSO47H2O, 2.5 CaC12, 1.2 NaH2PO4, 2.6 NaHCO5, 11.1
glucose, pH 7.4. The ureters were cannulated (PE 60) in order to
collect ureteral and venous effluent separately. Kidneys were
studied under basal tone (40 mm Hg). Renal perfusion pressure
was measured with a Harvard pressure transducer and recorded
on a Soltec 1242 pen recorder.
Perftisate collection after Ang II injection and infusion of P450
inhibitors
In order to quantify the AA metabolites present in renal
perfusates following close-arterial injection of Ang 11(50 ng) or
vehicle control (100 jd Krebs' solution), indomethacin (2.8 /LM)
was perfused through the kidneys from the outset of the experi-
ment and the renal venous and ureteral perfusates were collected
for five minute periods. After 30 minutes of perfusion, a basal
(control) collection was made followed by an injection of Ang II
after a 20 minute interval. To examine the effect of P450 inhibition
on the responses to Ang II, perfusates (ureteral and venous) were
collected during the administration of either Ang II or vehicle
control before and after infusion of P450 inhibitors. As the
available inhibitors lack selectivity, two mechanistically different
P450 inhibitors were studied, clotrimazole (1 jIM) [6] and 17-
octadecynoic acid (17-ODYA; 1 jIM) [71. The inhibitors were
perfused for 15 minutes prior to basal collection. Each kidney was
treated with only one P450 monooxygenase inhibitor. In time
controlled experiments (approximately 2 hr), the responses to
Ang II and resultant P450-HETE release in the absence of P450
inhibitors were reproducible. To measured volumes of renal
perfusates, 1 ng/ml of deuterated (co-D3) I 9-HETE was added as
an internal standard.
In order to verify inhibition of P450 activity, control and
17-ODYA-treated kidneys were homogenized and incubated (I
mg protein/mi) with NADPH (1 mM) and 14C-AA (7 jsM) for 30
minutes at 37°C. The incubates were extracted and the conversion
of radiolabeled AA to P450-AA metabolites was assessed using
H PLC, as described below.
Purification of P450-HE TEs
The samples were extracted twice with two volumes of acidified
ethyl acetate (pH 4.0) and then washed with water and evaporated
to dryness. A standard curve with known amounts of D3 19-HETE
and varying amounts of 19-HETE was set up with each experi-
ment and extracted in Krebs'-Henseleit solution as described
above. The samples and standards were purified by reverse-phase
(RP) HPLC on a C18 j Bondapak column (4.6 mm >< 24 mm)
using a linear gradient from acetonitrile:water:acetic acid (62.5:
37.5:0.05%) to acetonitrile (100%) over 20 minutes at a flow rate
of I ml/min. Fractions containing P450-HETEs were collected
based on the elution profile of standards monitored by UV
absorbance (205 nm). The fractions were evaporated to dryness
and derivatized for GC-MS analysis. Radiolabeled samples were
extracted and separated as described above and radioactivity was
monitored by an on line radiodetector (n-RAM; INUS Systems).
Quantitation of esterifled I-fETEs
The cortex and outer medulla were separated and each homog-
enized in methanol:water (1:1) and lipids extracted using the
Bligh/Dyer method [8]. We took precautions to prevent sponta-
neous oxidation of AA during isolation and handling of renal
lipids by including 0.1 m of the antioxidant triphenylphosphine
in all buffers. The lipid extracts were separated by normal-phase
HPLC on a 10 jIM Partisil 10 column (4.6 X 250 mm; Whatman)
using an isocratic system containing hexane/isopropanol/etha-
nol/SO m sodium acetate (pH 6.7)/acetic acid (300:260:120:30:1)
[9]. The flow rates were I mi/mm for 20 minutes and 1.5 mi/mm
for 40 minutes. This procedure separated neutral lipids (NL) and
the major phospholipid classes into phosphatidylethanolamine
(PE), phosphatidylinositol (P1), phosphatidylserine (PS) and
phosphatidylcholine (PC). The molecular species of endogenous
renal lipids were detected by UV monitoring at 206 nm and
identified by comparison of elution times with authentic lipid
standards [9] that were obtained from egg yolk (Sigma). The
phosphorus content of an aliquot of sample was measured using a
colorimetric method based on spectrophotometric absorbance
measurement of phosphomolybdate at 800 nm [10]. The remain-
ing fractions were subjected to alkaline hydrolysis (200 jIl meth-
anol and 100 d potassium hydroxide (0.2 M) for 2 hours at 50°C).
Unlike the phospholipids, the NL fraction was divided prior to
hydrolysis so that free fatty acids (P450-HETEs) could be quan-
titated. As an internal standard, 2 ng of D3 19-HETE was added
and the incubates extracted with 2 volumes of ethyl acetate (pH
4.0). The extracts were separated by RP-HPLC (as described
above) and the HETE fractions were derivatized and analyzed by
GC-MS.
Derivatization and mass spectrometric analyses
Pentafluorobenzyl (PFB) esters were prepared by the addition
of a-bromo-2,3,4,5,6-pentafluorotoluene (pentafluorobenzylbro-
mide, 5 tl, Aldrich) and N,N-diisopropylethylamine (5 pi, Al-
drich) to a sample dissolved in acetonitrile (100 pA), and the
derivatization was continued at room temperature for 30 minutes
[1, 11]. Trimethyisilyl (TMS) ethers of hydroxyls were prepared by
dissolving the sample in N,O-bis(trimethylsiiyl)trifluoroacetamide
(80 pA; Sigma), and the reaction was continued at room temper-
ature for 30 minutes. To separate subterminal P450-HETEs,
samples were dissolved in iso-octane and I pA aliquots were
injected into a GC (HP5890) column (DB-1; 15.0 m; 0.25 mm;
inner diameter 0.25 jIm film thickness; Supelco) using a temper-
ature program ranging from 150°C to 300°C at a rate of 10°C/mm
[121. Methane was used as a reagent gas at a flow resulting in a
source pressure of 1.3 torr, and the MS (Hewlett-Packard 5989A)
was operated in the electron capture chemical ionization mode.
The endogenous P450-HETEs were identified (ion m/z 391) by
comparison of GC retention times, with authentic P450-HETE
standards synthesized by us and quantitated by calculating the
ratio of abundance with D3 19-HETE (m/z 394).
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Table 1. Ureteral and venous P450-HETE release (ng/min)
Control Ang II 17-ODYA Ang II + 17-ODYA
Ureteral
16- 1.55 0.6 1.57 0.5 0.19 01b 1.78 0.9"
17- 5.94 1.9 4.72 1.5 0.07 002b 3.05 1.2"
18- 0.63 0.3 1.79 1.2 0.12 0.02k' 0.78 0.3"
19- 0.56 0.2 1.35 0.6 ND' 1.57 0.6"
20- 0.93 0.7 2.31 0.9" ND" 0.93 0.4"
Venous
16- 0.1 0.05 0.3 0.1 0.1 0.08 0.4 0.1"
17- 0.3 0.1 0.6 0.2" 0.1 0.07 0.4 0.2"
18- 0.1 0.08 0.4 0.2 0.1 0.05 0.3 0.1"
19- 0.5 0.2 1.0 0.2" 0.03 0.0l' 0.5 0.3"
20- 0.1 0.5 0.3 0.05" 0.06 0.03" 0.2 0.07c
Data are mean sEal; N = 6. Abbreviations arc Ang II, angiotensin 11(50 ng); 17-ODYA, 17-octadecynoic acid (1 /.tM).
ND, not detected.
Significant stimulation from control values
Significant reduction compared to control values
"Significant stimulation compared to 17-ODYA values
Statistical analysis
Comparisons among several groups were made by analysis of
variance followed by a modified t-test. Paired analyses were used
when comparisons were made of data obtained from the same
experimental preparation (that is, basal and stimulated levels).
Unpaired comparisons were used when the values were obtained
from different kidneys. Data are expressed as mean standard
error and a P value of < 0.05 was considered significant.
Results
Renal efflux of P450-HE TEs
Efflux of P450-HETEs into venous and urinary/ureteral efflu-
ents differed quantitatively and qualitatively (Table 1). Ureteral
efflux of P450-HETEs exceeded venous efflux by 5- to 25-fold
except for 19-HETE, the major venous HETE. 17-HETE was the
principal urinary HETE (5.94 1.5 nglmin). Ang II increased
20-HETE efflux from the urinary compartment and 17-, 19- and
20-HETE efflux from the venous compartment, each by twofold.
Inhibition of P450-.AA metabolism by 1 7-ODYA
Infusion of 17-ODYA (1 /.rM), at a concentration that was
reported to completely block AA conversion to P450 metabolites
by renal microsomes 171, virtually abolished basal ureteral efflux of
HETEs. Venous efflux of HETEs, while reduced by 17-ODYA,
was less affected (Table 1). We determined whether 17-ODYA (1
I.LM) inhibited P450 activity in the rabbit kidney under these
experimental conditions. The conversion of '4C-AA to P450-
HETEs by renal homogenates was inhibited by 70 5% in the
kidneys pretreated with 17-ODYA compared to control kidneys(N = 3; 36 4% to 10 2%, respectively; Fig. 1). Despite
pronounced inhibitory effects of 17-ODYA on basal renal efflux of
HETEs, the ability of Ang II to stimulate efflux of P450-HETEs
was unaffected by 17-ODYA (Table 1), as shown for 20-HETE in
Figure 2.
Inhibition of P450-AA metabolism by clotrimazole
Clotrimazole (1 lsM) differs mechanistically from 17-ODYA as
an inhibitor of P450-AA metabolism [131. Clotrimazole sup-
pressed basal renal efflux of HETEs to the same extent as
17-ODYA and, like 17-ODYA, did not prevent Ang Il-induced
0 5 10 15 20 25 30
Time, minutes
Fig. 1. Radiochromatograms of reverse-phase (RP) HPLC separation of
renal cortical homogenates: effect of] .LM 17-octadecynoic acid (17-ODYA).
Control (A) and 17-ODYA (B)-treated kidneys were homogenized and
incubated (1 mg protein/ml) with NADPH (1 mM) and 7 .LM '4C
arachidonie acid (AA) for 30 minutes at 37°C. The incubates were
extracted and the conversion of AA to radiolabeled metabolites was
assessed using reverse-phase HPLC. PGs, prostaglandins.
increased efflux of HETEs. Thus, in response to clotrimazole,
basal effluxes of 19- and 20-HETEs into the ureter were unde-
tectable, whereas in response to the Ang II challenge, ureteral
efflux of 19- and 20-HETEs rose to 1.18 0.74 and 2.06 1.63
ng/min, respectively (P < 0.05). On the other hand, venous
effluxes of 19- and 20-HETEs were still detected after clotrim-
azole (0.36 0.17 and 0.13 0.04 ng/min, respectively), and were
increased two- to threefold by Ang II (P < 0.05).
Distribution of renal HETEs: Frec, neutral lipids and
phospholipids
These findings, that inhibition of P450-dependent AA metabo-
lism did not prevent Arig Il-induced release of HETEs, may be
10
x 6
0
2
10
0
2
A
metabolites
PGs
—.
0 5 10 15 20 25 30
B
Carroll et al: Esterified renal P450-HE TEs 1699
explained by the incorporation of HETEs into tissue lipids from
which site they are subject to release by appropriate stimuli. To
obtain definitive evidence that P450-HETEs were preformed and
stored in the kidney, extracted cortical and medullary lipids were
separated on HPLC and fractions collected corresponding to
retention times of authentic lipid standards. The P450-HETEs
were derivatized by GC-MS and quantitated following alkaline
hydrolysis of individual lipid fractions. Esterified HETEs were
found in larger quantities in the cortex as compared to the
medulla (34.40 1.12 versus 22.76 0.53 ng/g of wet wt tissue).
The P450-HETEs were contained in both neutral lipids and
phospholipid fractions in the cortex and medulla (Fig. 3; Tables 2
and 3). The PT fraction in the cortex yielded the largest quantity of
HETEs and the PC fraction the lowest (Fig. 3). In the medulla,
the largest quantities of esterified HETEs were found in neutral
lipids, and only slightly lesser amounts in PE and PT.
Free fatty acids were detected in larger quantities in the
medulla than in the cortex (4.50 0.77 vs. 1.88 0.45 nglg wet wt
tissue), 19- and 20-HETEs accounting for all of the free form in
the cortex and greater than 95% in the medulla (Table 2). For
neutral lipids, 20-HETE was the principal HETE recovered after
hydrolysis, accounting for ca 40 and 70% of HETEs bound to
neutral lipids in the cortex and medulla, respectively. 19-HETE
was also bound to neutral lipids in relatively large quantities as
compared to 16- and 17- HETEs. 18-HETE, not detectable in
15
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w
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Fig. 3. Renal distribution of esterified P450-HETEs. The cortex () and
outer medulla () were separated and lipids extracted. The extracts were
separated by normal-phase HPLC. This procedure separated neutral
lipids (NL) and the major phospholipid classes: phosphatidylethanolamine
(PE), phosphatidylinositol (P1), phosphatidylserine (PS) and phosphati-
dyleholine (PC). The molecular species of endogenous renal lipids were
detected by UV monitoring at 206 nm and identified by comparison of
elution times with authentic lipid standards. The fractions were subjected
to alkaline hydrolysis. Unlike the phospholipids, the NL fraction was
divided prior to hydrolysis so that free fatty acids (FFA) could be
quantitated. The extracts were separated by RP-HPLC, the HETE
fractions derivatized and analyzed by GC-MS. The assignment of a HETE
to a specific phospholipid pool must be regarded as tentative as the
appropriate standards containing P450-HETEs in the Sn-2 position (such
as 20-HETE-PE, 20-HETE-PC, etc.) were not available.
phospholipids, was found almost entirely in the neutral lipid
fraction of the cortex (Table 3) and 17-HETE was restricted
primarily to neutral lipids and to FE of both zones.
The cortex contained the largest quantities of 19- and 20-
HETEs which were preferentially esterified to PT in both cortex
and medulla (ca 35% of 19-HETE and 50% of 20-HETE were
found in P1; Table 3). Moderate quantities of 16-HETE were also
incorporated into PT. PE yielded only 16- and 17-HETEs. Cortical
PS and PC contained primarily 19- and 20-HETEs, each in lesser
quantities than were incorporated into P1.
Discussion
We have reported that Ang II stimulated release from the
rabbit kidney of 20-HETEs as well as the subterminal HETEs, 16-,
17-, 18- and 19-HETEs. We were particularly interested in
20-HETE as it acts as a key component in several important renal
regulatory systems, including autoregulation of renal blood fowl
GFR [14], modulation of the mTAL cotransporter [21 and gb-
merular tubular feedback [15]. As a first step in determining sites
of interaction of Ang II and P450-dependent monooxygenases, we
have defined the profile of P450-HETEs released into renal
venous and ureteral effluents before and after stimulation by Ang
Ii. The urinary and venous profiles of P450-HETEs differed
quantitatively and qualitatively under basal conditions (Table 1).
Urinary efflux of P450-HETEs was 5- to 20-fold higher than
venous efflux, excepting 19-HETE, which demonstrated compa-
rable levels in ureteral and venous effluents. 17-HETE predomi-
nated in the ureteral effluent, effluxing at a rate greater than
tenfold that of 19-HETE, the principal HETE in the venous
effluent. I 7-ODYA effectively inhibited P450-AA metabolism as it
abolished basal ureteral efflux of 20- and 19-HETEs and signifi-
cantly reduced that of 16-, 17, and 18-HETEs (Table 1). None-
theless, Ang II was still capable of stimulating ureteral and venous
P450-HETE efflux in the presence of 17-ODYA. For example,
A
4000 Ureter *
* T
a
3200
2400
1600
800
0
4000
3200
2400
1600
800
0
Basal Ang II Basal Ang II Basal Ang II
B Control 17-ODYA Clotrimazole
Venous
* * *
Basal Ang II Basal Ang II
Control 1 7-ODYA
Basal Ang II
Clotrimazole
Fig. 2. The effect of P450 inhibitors on 20-HETE efllux. Ureteral and
venous perfusates were collected after close arterial injection of vehicle
(Basal; 100 j.d Krebs') or Ang II (angiotensin IT) before (Control) and
after I !.LM 17-ODYA (17-octadecynoic acid) or I u cbotrimazole. *J) <
0.05 compared to basal.
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Table 2. Distribution of P450-HETEs among neutral lipids (ng/g wet weight tissue)
16- 17- 18- 19- 20-
Cortex
Free FA Trace Trace Trace 084 0.34 1.04 0.59
NL 0.49 0.25 0.40 0.12 1.56 0.56 1.28 0.52 2.71 1.49
Medulla
Free FA Trace Trace 0.16 0.09 1.58 0.84 2.76 1.39
ML Trace 0.72 0.21 0.17 0.08 1.20 0.71 4.87 1.78
Data are mean SEM; N = 6. Abbreviations are: FA, fatty acid; NL, neutral lipids.
Table 3. Distribution of P450-HETE among phospholipids
(nmol 1-IETE/jLmol phosphorus)
16- 17- 18- 19- 20-
Cortex
PE
P1
PS
PC
Medulla
PE 15±4 10±6 ND ND ND
P1 6±2 3±1 ND 23±3 23±6
PS Trace Trace ND 15 7 6 3
PC 4 2 Trace ND Trace 8 5
Data are: mean scM; N = 6. Abbreviations are: PE, phosphatidyleth-
anolamine; P1, phosphatidylinositol; PS, phosphatidylserine; PC, phos-
phatidylcholine; ND, not detected. The assignment of a HETE to a
specific phospholipid poo1 must be regarded as tentative as the appropri-
ate standards containing P450-HETEs in the Sn-2 position (such as,
20-HETE-PE, 20-HETE-PC, etc.) were not available.
basal ureteral efflux of 17-HETE was greatly reduced by 17-
ODYA from 5.94 to 0.07 ng/min. However, the P450 inhibitor did
not prevent Ang Il-induced release of 17-HETE to levels of
3.05 1.2 ng/min exceeding those of basal by more than 40-fold.
Clotrimazole, a P450-AA inhibitor that differs from 17-ODYA
structurally and mechanistically, demonstrated effects similar to
those obtained with 17-ODYA. Similar results to those indicated
above for 17-HETE were obtained for Ang 11-stimulated 20-
HETE effiux (Fig. 2). Ang TI-induced release of 20-HETE was not
prevented by inhibiting P450 monooxygenase activity with either
17-ODYA or clotrimazole. These results suggest that P450-
HETEs are preformed in the kidney, are bound to renal lipids,
and can be released from renal lipids by Ang II, possibly by a
receptor-mediated stimulation of phospholipases (PLs) such as
PLA2 (161.
Of the eicosanoids, only epoxides and HETEs can be incorpo-
rated into cellular lipids. Karara et al [4] have reported that
alkaline hydrolysis of renal lipids yielded concentrations of EETs
in the human renal cortex of 333 nglg wet wt of tissue similar to
those reported for rabbit [17] and rat kidneys [18], a value about
tenfold greater than the rabbit renal cortical concentration of
HETEs. Thus, alkaline hydrolysis of rabbit renal cortical and
medullary lipids yielded 34 and 22 ng/g wet wt of tissue, respec-
tively. Comparable differences between preformed EETs and
HETEs obtained in human platelets; viz., hydrolysis of platelet
lipids resulted in recovery of EETs in 100-fold greater quantities
than HETEs [19].
The principal renal HETE recovered from renal effluents,
17-HETE, was found only in small quantities, primarily bound to
neutral lipids and PE (Tables 2 and 3). The rapid and large
response of 17-HETE to Ang II in the face of P450 inhibition is in
keeping with a renal lipid storage pool of 1 7-HETE that responds
to Ang II activation of a lipase. This pool is presumably contigu-
ous to the urinary compartment as ureteral effiux of 17-HETE
exceeded venous by seven- to eightfold when challenged with Ang
II. Moreover, the capacity of Ang II to release 17-HETE was
unaffected by treatment with 17-ODYA. 16-HETE, the second
most abundant HETE effluxing from the kidney, was highly
concentrated in P1 as were 19- and 20-HETEs. Unlike 19- and
20-HETEs, however, 16-HETE was also found in large quantities
in PE, being the only HETE, other than small quantities of
17-HETE, bound to this phospholipid. However, the assignment
of a HETE to a specific phospholipid pooi requires a cautionary
as the phospholipid standards used to determine collection of
lipid fractions contained AA in the Sn-2 position as, for example,
AA-PE. As the appropriate standards containing P450-HETEs in
the Sn-2 position (such as 20-HETE-PE, 20-HETE-PC, etc.) were
not available, we used phospholipid standards (PE, PC, PT, PS).
Thus, the identification of a specific PL to which P450-HETEs are
acylated must be regarded as tentative until confirmed by com-
parison of normal phase retention times and quantitation by
GC-MS with authentic P450 standards (such as 20-HETE-PE,
etc.). This reservation, however, does not lessen the basic obser-
vation in our study, that a considerable reservoir of P450-derived
HETEs are stored in renal lipids and can be released in response
to an appropriate agonist.
Faick and coworkers [17] and Ballou et al [20] have reported on
epoxide liberation from cellular lipids in response to either
alkaline hydrolysis or PLA2 treatment. Most studies have followed
incorporation of either exogenous P450-AA metabolites [21, 22]
or HETEs of lipoxygenase origin (5-, 12- and 15-HETEs) into
cellular lipids [23—25]. Direct comparison of studies that are based
on uptake of radiolabeled EETs/HETEs to our findings in order
to define distribution of HETEs among tissue lipids can he
misleading, as exogenous HETEs added to isolated cells or cells in
culture may not reproduce the distribution of endogenous HETEs
synthesized in intact organs. Indeed, in a recent study [26] we
examined the HPLC retention times of radiolabeled 20-HETE
esterified to PE and P1 and found the retention times of 20-
HETE-PE and 20-HETE-PI to be different from those of AA-PE
and AA-PI, respectively. We assayed endogenous P450-HETEs by
a specific and sensitive method based on electron capture chem-
ical ionization GC-MS after release of bound HETEs from renal
lipids by alkaline hydrolysis. We used alkaline hydrolysis to
liberate HETEs from lipids, as this procedure released all HETEs
from phospholipid stores. In contrast, the use of PLA2, such as
that obtained from cobra venom, has been shown to demonstrate
substrate specificity; for example, PE "is not efficiently hydrolyzed
by PLA2" [19]. We confirmed HETE binding to phospholipids by
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demonstrating the release of relatively large amounts of HETEs
from lipid fractions subject to alkaline hydrolysis. We also de-
tected significant quantities of HETEs that were free, that is,
unbound to lipids. The functional significance of "free" HETEs
awaits isolation of individual renal components as, for example,
mTAL cells, and analysis of the distribution of the cellular HETE
content within specific structures before and after exposure to
physiological stimuli. A caveat is in order, namely, "free" HETEs
may represent, in part, a liberation of HETEs from renal lipids
during isolation and purification of lipids present in renal cortical
and medullary homogenates. However, in a recent study, we used
similar methods for isolation and purification of platelet lipids but
did not detect free/unbound HETEs [19].
The possibility warrants consideration that AA, esterified to
phospholipids and diacylglycerol, can be directly oxidized to form
HETEs in addition to esterification of free HETEs to lysophos-
pholipids.A priori, lipid-containing HETEs may result from either
esterification of HETEs to lysophospholipids or oxidation of AA
and acylated at the Sn-2 position of phospholipids. Karara et a!
[27] have excluded the possibility that AA esterified to hepatic
lipids can be oxidized to epoxides (EETs) by P450 enzymes. On
the other hand, reticulocyte lipoxygenase has been shown to
directly oxygenate membrane lipids [28].
Significant quantities of HETEs must have occupied the Sn-2
position as Ang II released relatively large quantities of HETEs
after inhibition of P450 monooxygenase activity with either 17-
ODYA or clotrimazole. This finding is best explained by stimu-
lation of PLA2 by the peptide [29], resulting in deacylation of the
substituent at the Sn-2 position of the phospholipid. Incorpora-
tion of HETEs into the Sn-2 position of phospholipids may be
tissue specific. A renal cell line, MDCK cultures, did not demon-
strate this specificity regarding 12-HETE [24], whereas bovine
aortic endothelial cells incorporated more than 90% of 12-HETE
into the Sn-2 position of PE and PC [30]. 15-HETE was also
incorporated primarily into the Sn-2 position of P1 in MDCK cells
[25]. The presence of a HETE in the Sn-2 position of PT was
shown to have functional implications for MDCK cells; for
example, 12-HETE, when incorporated into MDCK cell phospho-
lipid pool, reduced prostaglandin production [24] and 15-HETE-
P1 resulted in release of altered second messengers in endothelial
cells [25]. The formation of diacylglycerides containing HETEs by
the action of PLC may affect the activation/stimulation of protein
kinase C (PKC) and cellular events dependent on PKC formation
[191. Signal transduction, via inositol-phospholipid hydrolysis,
therefore may be affected by HETEs incorporated into tissue
lipids.
The stereochemical determinants of P450-HETE esterification
to tissue lipids were not addressed, as the cnantiomer composition
of the released HETEs was not determined. We have described
stereochemical-dependent biological activities of the subterminal
HETEs, for example 16(S) HETE inhibits ATPase while the (R)
form, devoid of this activity, is vasoactive at the same concentra-
tion. 16(R) HETE [1], also identified in neutrophils, had unex-
pected properties that include inhibition of neutrophil adhesion
and aggregation [31].
Our findings suggest that preformed HETEs are integral com-
ponents of renal lipids and are subject to release by Ang II-
stimulated receptor-mediated hydrolysis of phospholipids. More-
over, these HETEs possess significant biological properties by
which they could act either on tubular transport or the renal
vasculature. For 20-HETE, both properties are evident. Defining
the spectrum of functional consequences that result from P450-
derived HETE binding to tissue lipids should uncover important
relationships between hormones and target tissue responses to
them. Finally, inhibition of P450 hydroxylase activity may not
prevent those actions of Ang II, intrarenally, that are related to
release of P450-derived mediators, as preformed HETEs bound
to renal lipids constitute a significant reservoir.
Acknowledgments
This research was supported in part by grants from the National
Institutes of Health HL34300 and the American Heart Association
90-075G. We thank Jennifer Brown for secretarial assistance and Melody
Steinberg for editorial assistance in preparing this manuscript.
Reprint requests to MaireadA. Carroll, Ph.D., Department of Pharmacol-
ogy, New York Medical College, Valhalla, New York 10595, USA.
References
1. CARROLL MA, BALAZY M, MARGIO1-ITA P, HUANG DD, FALCK JR,
MCGIFF JC: Cytochrome P450-dependent HETEs: Profile of biolog-
ical activity and stimulation by vasoactive peptides. Am J Physiol
271:R863—R869, 1996
2. ESCALANTE B, ERLIJ D, FALCK JR, MCGIFF JC: Effect of cytochrome
P450 arachidonate metabolites on ion transport in rabbit kidney loop
of Henle. Science 251:799—802, 1991
3. MA YH, GEBREMEDHIN D, SCHWARTZMAN ML, FALCK JR, CLARK JE,
MASTERS BS, HARDER DR, ROMAN RJ: 20-Hydroxyeicosatetraenoic
acid is an endogenous vasoconstrictor of canine renal arcuate arteries.
Circ Res 72:126—136, 1993
4. KARARA A, DISIIMAN E, JACOBSON H, FALCK JR, CAPDEVILA JH:
Arachidonic acid epoxygenase. Stereochemical analysis of the endog-
enous epoxyeicosatrienoic acids of human kidney cortex. FEBS Lett
268:227—230, 1990
5. CARROLL MA, GARCIA MP, FALCK JR, MCGIFF JC: Cyclooxygenase
dependency of the renovascular actions of cytochrome P450-derived
arachidonate metabolites. J Pharmacol Exp Ther 260:104—109, 1992
6. FULTON D, MAHBOUBI K, MCGIFF JC, QUILLEY J: Cytochrome
P450-dependent effects of bradykinin in the rat heart. BrJ Pharmacol
114:99—102, 1995
7. Zoo AP, MA YH, Sul ZH, ORTIZ DR MONTELLANO PR, CLARK JE,
MASTERS BS, ROMAN RJ: Effects of 17-octadecynoic acid, a suicide-
substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase,
on renal function in rats. J Pharmacol Exp Ther 268:474—481, 1994
8. BLIGH E, DYER W: A rapid method of total lipid extraction and
purification. Can J Biochem Physiol 37:911—917, 1959
9. PATTON G, ROBBINS S: Extraction of phospholipid molecular species,
in Methods in Enzymology, edited by MURPHY RC, FITZPATRICK FA,
San Diego, New York, Boston, London, Academic Press mc, 1990, p
195
10. BARTLETF G: Phosphorous assay in column chromatography. J Biol
Chem 234:466-468, 1959
11. Ciu.oi, MA, GARCIA MP, FALCK JR, MC:GIFF JC: 5,6-cpoxyeicosa-
trienoic acid, a novel arachidonate metabolite. Mechanism of vasoac-
tivity in the rat. Circ Res 67:1082—1088, 1990
12. MACICA C, BALAZY M, FALCK JR, MIosKowsKI C, CARROLL MA:
Characterization of cytochrome P-450-dependcnt arachidonic acid
metabolism in rabbit intestine. Am J Physiol 265:G735—4l, 1993
13. MURRAY M, REIDY GF: Selectivity in the inhibition of mammalian
cytochromes P-450 by chemical agents. Pharmacol Rev 42:85—101,
1990
14. Zoo AP, 1Mb JD, KALDUNSKI M, ORTIZ DR MONTELLANO PR, Sul Z,
ROMAN RJ: Inhibition of renal vascular 20-HETE production impairs
autoregulation of renal blood flow. Am J Physiol 266:F275—F282, 1994
15. Zoo AP, lsilG JD, ORTIZ DE MONTELLANO PR, 501 Z, FALCK JR,
ROMAN RJ: Effect of P-450 omega-hydroxylase metabolites of arachi-
donic acid on tuhuloglomerular feedback. Am J Physiol 266:F934—
F94l, 1994
1702 Carroll et al: Estenfied renal P450-HETEs
16. DOUGLAS JG, HOPFER U: Novel aspect of angiotensin receptors and
signal transduction in the kidney. Ann Rev Physiol 56:649—669, 1994
17. FALCK JR, SCHUELER VJ, JACOBSON HR, SIDDHANTA AK, PRAMANIK
B, CAPDEVILA J: Arachidonate epoxygenase: Identification of epoxyei-
cosatrienoic acids in rabbit kidney. J Lipid Res 28:840—846, 1987
18. TAKAHASIII K, CAPDEVILA J, KARARA A, FALCK JR, JACOBSON HR,
BADR KF: ytochrome P-450 arachidonate mctabolites in rat kidney:
Characterization and hemodynamic responses. Am J Physiol 258:
F781—F799, 1990
19. ZHU Y, SCHIEBER EB, MCGIFF IC, BALAZY M: Identification of
arachidonate P-450 metabolites in human platelet phospholipids.
Hypertension 25:854—859, 1995
20. BALLOU LR, LAM BK, WONG PY, CI-IEUNG WY: Formation of
cis-14,15-oxido-5,8,1 1-icosatrienoic acid from phosphatidylinositol in
human platelets. Proc NatI 4 cad Sci USA 84:6990—6994, 1987
21. FANG X, VANROLLINS M, KADUCE TL, SPEcTOR AA: Epoxyeicosatri-
enOic acid metabolism in arterial smooth muscle cells. J Lipid Res
36:1236—1246, 1995
22. BERN5TROM K, KAYGANICFI K, MURPHY RC, FITZPATRICK FA: Incor-
poration and distribution of epoxyeicosatrienoic acids into cellular
phospholipids. J Biol Chem 267:3686—3690, 1992
23. GORDON JA, FIGARD PH, QUINBY GE, SPECTOR AA: 5-HETE:
Uptake, distribution, and metabolism in MDCK cells. Am J Physiol
256:C1—C10, 1989
24. GORDON IA, SPECTOR AA: Effects of 12-HETE on renal tubular
epithelial cells. Am J Physiol 253:C277—C285, 1987
25. GIRTON RA, SPECTOR AA, GORDON JA: 15-HETE: Selective incor-
poration into inositol phospholipids of MDCK cells. Kidney mt
45:972—980, 1994
26. YING Z, MCGIFF JC, BALAZY M: Identification of 20-hydroxyeicosa-
tetraenoic acid in rat kidney phospholipids. (abstract) 43rd ASMS
Confrrence on Mass Spectrometiy and Allied Topics, 1995, p 1148
27. KARARA A, DISHMAN E, BLAIR I, FALCK JR, CAPDEVILA JH: Endog-
enous epoxyeicosatrienoic acids. Cytochrome P-450 controlled stereo-
selectivity of the hepatic arachidonic acid epoxygenase. J Biol Chem
264:19822—19827, 1989
28. KUHN H, BELKNER J, WIESNER R, BRASH AR: Oxygenation of
biological membranes by the pure reticulocyte lipoxygenase. J Biol
Chem 265:18351—18361, 1990
29. ANDREATTA VAN LEYEN 5, ROMERO MF, KI-IOSLA MC, DOUGLAS JG:
Modulation of phospholipase A2 activity and sodium transport by
angiotensin-(1—7). Kidney mt 44:932—936, 1993
30. WANG LX, KADUCE TL, SPECTOR AA: Localization of 12-hydroxyei-
cosatetraenoic acid in endothelial cells.J Lipid Res 31:2265—2276, 1990
31. BEDNAR MM, COLELLA DT, GROSS CE, BALAZY MK, BALAZY M:
16-HETE: A novel arachidonate metabolite which inhibits human
leukocyte function. (abstract) Prostaglandins and Related Compounds,
1994
